At Aptose Biosciences, we are building a pipeline of novel and targeted oncology therapies with the potential to serve specific populations of cancer patients.
Our pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of conventional anti-cancer therapies through simultaneous targeting of key drivers of disease in cancer cells without overlapping toxicities and thus preserving the quality of life in cancer patients.